Anthony Yazbeck: Why the Hemolysin Test Matters More Than You Think
Anthony Yazbeck, Application Specialist at Atom Medical-Dora, shared a post on LinkedIn:
”Why the Hemolysin Test Matters More Than You Think
In transfusion medicine, compatibility goes beyond ABO typing — and this is where the hemolysin test becomes critical.
Hemolysins are antibodies capable of destroying red blood cells, particularly anti-A and anti-B, which play a major role in non-identical (non-iso) group transfusions.
Why does this matter?
In group O donors, plasma may contain anti-A and anti-B antibodies. When transfused into A, B, or AB recipients, these antibodies can attack the recipient’s red blood cells, leading to hemolytic transfusion reactions.
While antibody titration is often used to assess risk, it only measures the quantity of antibodies — not their ability to cause damage.
The real clinical concern lies in hemolysins: antibodies that can actively activate complement and destroy red blood cells.
This is why hemolysin testing is essential:
- Detects clinically significant anti-A and anti-B hemolysins
- Adds functional insight beyond antibody titers
- Reduces risk in non-iso group transfusions
- Strengthens donor selection and blood safety
In resource-limited settings, overlooking this step can increase transfusion risks. Strengthening awareness and implementation of hemolysin screening can make a life-saving difference.
Safe blood isn’t just about how much antibody is present — but what it can do.”
Stay updated withHemostasis Today.
-
Mar 24, 2026, 17:12Ron DePinho: CRISPR Progress in Cellular Immunotherapy
-
Mar 24, 2026, 17:12Martine Gilard։ Women’s Heart Health as a National Priority
-
Mar 24, 2026, 17:11Erik Nelson։ Blood Vessels – The Silent System That Determines How You Age
-
Mar 24, 2026, 17:09Marcos Gamboa Chele: Are We Asking for Too Many Thrombophilia Panels?
-
Mar 24, 2026, 17:06Anita Brikman: PPTA Explores India’s Growing Plasma-Derived Medicines Industry
-
Mar 24, 2026, 17:01Victor Canata: Is Embolectomy the Best Treatment for Pulmonary Thromboembolism?
-
Mar 24, 2026, 16:57Hossam Qassem: The Stepwise Investigation Framework for ICU Hemoglobin Drop
-
Mar 24, 2026, 16:56Alan Nurden: Targeting Splice Site Variants in Alport Syndrome with Antisense Therapy
-
Mar 24, 2026, 16:53Nibia Gómez Joins the WFH PACT Advocacy Academy